Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555397 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
A Phase 1 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02555397 is a Phase 1 study that has completed, run by Henry Ford Health System. The registered enrollment target is 15 participants.
The verdict
NCT02555397, a Phase 1 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy
Interventions
- BIOLOGICAL Ad5-yCD/mutTKSR39rep-hIL12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-08 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02555397
The ClinicalTrials.gov registry entry for NCT02555397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad5-yCD/mutTKSR39rep-hIL12 is the first listed.
NCT02555397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02555397 about?
NCT02555397 is a clinical study titled "Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer". The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy
What is the current status of trial NCT02555397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-08. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT02555397?
The interventions under investigation include: Ad5-yCD/mutTKSR39rep-hIL12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02555397?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.